N-Acetyl Semax

Scientific Overview

N-Acetyl Semax is an N-terminal acetylated derivative of Semax (the ACTH(4-7) analog Pro-Gly-Pro fragment) developed at the Russian Institute of Molecular Genetics. Acetylation blocks aminopeptidase cleavage, extending half-life. Like Semax it raises BDNF/NGF and modulates dopaminergic tone. Schedule status varies; not FDA-approved.

Citations (4)

1. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodentsPubMed
2. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampusPubMed
3. The neuroprotective effects of Semax in conditions of MPTP-induced lesions of the brain dopaminergic systemPubMed
4. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrainPubMed

Dosages listed are common research protocols found in peer-reviewed literature and clinical trials. Individual results and requirements may vary significantly in a research context.

Key Research Benefits

• Memory and focus
• BDNF/NGF upregulation
• Longer half-life vs Semax

Potential Side Effects

Labs to monitor

Educational context only, not a testing mandate. Any bloodwork decisions belong with your clinician.

• No validated compound-specific markers: No standard bloodwork is established for this compound; general safety labs (CBC, comprehensive metabolic panel) are reasonable if used under medical supervision.